TY  - JOUR
AU  - Climent, Miguel A
AU  - Font, Albert
AU  - Duran, Ignacio
AU  - Puente, Javier
AU  - Mendez-Vidal, Maria Jose 
AU  - Saez, Maria Isabel
AU  - Santander-Lobera, Carmen
AU  - Angel-Arranz-Arija, Jose
AU  - Gonzalez-Del-Alba, Aranzazu
AU  - Sanchez-Hernandez, Alfredo
AU  - Juan-Fita, Maria Jose
AU  - Esteban, Emilio
AU  - Alonso-Gordoa, Teresa
AU  - Mellado-Gonzalez, Begoña
AU  - Maroto, Pablo
AU  - Lazaro-Quintela, Martin
AU  - Cassinello-Espinosa, Javier
AU  - Perez-Valderrama, Begoña
AU  - Garcias, Carmen
AU  - Castellano, Daniel
PY  - 2022
DO  - 10.1016/j.ejca.2022.08.002
UR  - http://hdl.handle.net/10668/22179
T2  - European journal of cancer (Oxford, England : 1990)
AB  - We aimed to compare the efficacy and safety of maintaining or withdrawing abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer who had experienced cancer progression to this treatment and were...
LA  - en
PB  - Elsevier
KW  - Abiraterone acetate
KW  - Combination
KW  - Docetaxel
KW  - Metastatic castration-resistant prostate cancer
KW  - Phase II
KW  - Abiraterone acetate
KW  - Antineoplastic combined chemotherapy protocols
KW  - Disease progression
KW  - Docetaxel
KW  - Humans
KW  - Male
KW  - Prednisone
KW  - Prostatic neoplasms, castration-resistant
KW  - Treatment outcome
TI  - A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.
TY  - research article
VL  - 175
ER  -